Table 2.

Steady-state pharmacokinetic parameters of NFV and EFV with and without levofloxacin in two groups of HIV-positive patients

HIV patient group and mean differencePharmacokinetic parameter (mean ± SD)
Ctrough(μg/ml)C1h(μg/ml)C2h(μg/ml)C12h(μg/ml)AUC0–2(μg · h/ml)aAUC0–8(μg · h/ml)bAUC0–12(μg · h/ml)cAUC0–24(μg · h/ml)d
NFV (n = 12)1.35 ± 0.711.34 ± 0.661.67 ± 1.262.85 ± 1.6112.56 ± 7.08
NFV + levofloxacin (n = 12)1.64 ± 0.731.72 ± 0.61.85 ± 0.63.47 ± 1.2415.28 ± 5.5
Mean difference (95% CI)e−0.299 (−0.815; 0.218)−0.379 (−0.806; 0.049)−0.179 (−0.908; 0.551)−0.614 (−1.619; 0.390)−2.714 (−7.135; 1.707)
EFV (n = 12)1.77 ± 0.953.74 ± 1.62.57 ± 1.8137.1 ± 19.0366.86 ± 36.31
EFV + levofloxacin (n = 12)2.23 ± 1.784.23 ± 3.232.59 ± 1.5140.59 ± 28.5384.35 ± 67.63
Mean difference (95% CI)−0.460 (−0.998; 0.077)−0.494 (−1.534; 0.547)−0.014 (−0.410; 0.382)−3.494 (−9.344; 2.356)−17.486 (−37.915; 2.942)
  • a Abbreviated NFV AUC calculated from 0 to 2 h.

  • b Total NFV AUC calculated by equation 1.

  • c Abbreviated EFV AUC calculated from 0 to 12 h.

  • d Total EFV AUC calculated by equation 2.

  • e CI, confidence interval.